Oral HPV infection clearance and acquisition after nonavalent vaccination in men who have sex with men and transgender women: a prospective analysis

被引:1
作者
Rossotti, Roberto [1 ,2 ]
Nava, Alice [3 ]
Baiguera, Chiara [1 ]
Baldassari, Luca [1 ,4 ]
Moioli, Maria Cristina [1 ]
Fanti, Diana [3 ]
D'Amico, Federico [1 ]
Calzavara, Daniele [2 ]
Bossolasco, Simona [2 ,5 ]
Tamburini, Andrea Marco [6 ]
Canetti, Diana [2 ,5 ]
Bana, Nicholas Brian [1 ,4 ]
Cernuschi, Massimo [2 ,5 ]
Vismara, Chiara [3 ]
Puoti, Massimo [1 ,4 ]
机构
[1] ASST Grande Osped Metropolitano Niguarda, Dept Infect Dis, Piazza Osped Maggiore 3, I-20162 Milan, Italy
[2] Milano Checkpoint ETS, Milan, Italy
[3] ASST Grande Osped Metropolitano Niguarda, Clin Microbiol, Milan, Italy
[4] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy
[5] Ist Sci San Raffaele, Dept Infect Dis, Milan, Italy
[6] Ist Sci Univ San Raffaele, Gastrointestinal Surg Unit, Milan, Italy
关键词
Oral HPV infection; Nonavalent vaccine; MSM; HIV; Pre-exposure prophylaxis; HUMAN-PAPILLOMAVIRUS VACCINATION; YOUNG-ADULTS; IMMUNOGENICITY; SAFETY; PREVALENCE; NEOPLASIA;
D O I
10.1007/s10096-024-04887-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Oral HPV infection is the main risk factor for the development of oropharyngeal carcinoma. Men who have sex with men (MSM), especially if living with HIV (PLWH), are at increased risk of infection and consequently of cancer development. Aim of this study is to evaluate the impact of nonavalent vaccine on oral HPV infection in a cohort of MSM and transgender women (TGW). This prospective study included all MSM and TGW who started nonavalent HPV vaccination from May 2019 to September 2021. Oral rinse was collected before each vaccine administration and after six months of follow up. Descriptive statistics were used. Kaplan Meier probability curves and Cox regression models for HPV acquisition and clearance were calculated. The analysis included 211 individuals (202 MSM and 9 TGW). PLWH were 138 (65.4%). Baseline oral rinse was positive in 30 subjects (14.2%). Positivity rate did not change over time (p = 0.742), even when restricting the analysis only to high-risk genotypes (p = 0.575) and to genotypes covered by vaccine (p = 0.894). The risk to acquire HPV infection was 12.8% at one year and 33.4% at two years after vaccination. The probability to clear the infection was 67.6% at one year and 87.9% at two years. HIV infection had no impact on vaccine efficacy. Age above 45 years was the only factor associated to HPV acquisition (aHR 4.06, 95% CI 1.03-15.98, p = 0.045). Prevalence of oral HPV infection was higher in PLWH, but HIV had no impact on viral clearance or acquisition after vaccination.
引用
收藏
页码:1847 / 1854
页数:8
相关论文
共 38 条
  • [11] Oral human papillomavirus (HPV) infection and HPV vaccination in an Australian cohort
    de Souza, Marjorie M. A.
    Hartel, Gunter
    Olsen, Catherine M.
    Whiteman, David C.
    Antonsson, Annika
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (02) : 417 - 426
  • [12] Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
    Gillison, Maura L.
    Chaturvedi, Anil K.
    Anderson, William F.
    Fakhry, Carole
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29) : 3235 - +
  • [13] Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men
    Giuliano, Anna R.
    Wilkin, Timothy
    Bautista, Oliver M.
    Cheon, Kyeongmi
    Connor, Laurie
    Dubey, Sheri
    Group, Thomas
    Luxembourg, Alain
    Rawat, Sonali
    Shaw, Anita
    Velicer, Christine
    Vendetti, Neika
    Tu, Yingmei
    [J]. CONTEMPORARY CLINICAL TRIALS, 2022, 115
  • [14] Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)-The MAM Study
    Giuliano, Anna R.
    Isaacs-Soriano, Kimberly
    Torres, B. Nelson
    Abrahamsen, Martha
    Ingles, Donna J.
    Sirak, Bradley A.
    Quiterio, Manuel
    Lazcano-Ponce, Eduardo
    [J]. VACCINE, 2015, 33 (42) : 5640 - 5646
  • [15] Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
    Giuliano, Anna R.
    Palefsky, Joel M.
    Goldstone, Stephen
    Moreira, Edson D., Jr.
    Penny, Mary E.
    Aranda, Carlos
    Vardas, Eftyhia
    Moi, Harald
    Jessen, Heiko
    Hillman, Richard
    Chang, Yen-Hwa
    Ferris, Daron
    Rouleau, Danielle
    Bryan, Janine
    Marshall, J. Brooke
    Vuocolo, Scott
    Barr, Eliav
    Radley, David
    Haupt, Richard M.
    Guris, Dalya
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05) : 401 - 411
  • [16] Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review
    Harder, Thomas
    Wichmann, Ole
    Klug, Stefanie J.
    van der Sande, Marianne A. B.
    Wiese-Posselt, Miriam
    [J]. BMC MEDICINE, 2018, 16
  • [17] Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old
    Hillman, Richard J.
    Giuliano, Anna R.
    Palefsky, Joel M.
    Goldstone, Stephen
    Moreira, Edson D., Jr.
    Vardas, Eftyhia
    Aranda, Carlos
    Jessen, Heiko
    Ferris, Daron G.
    Coutlee, Francois
    Marshall, J. Brooke
    Vuocolo, Scott
    Haupt, Richard M.
    Guris, Dalya
    Garner, Elizabeth I. O.
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (02) : 261 - 267
  • [18] Prevalence of oral human papillomavirus by vaccination status among young adults (18-30 years old)
    Hirth, Jacqueline M.
    Chang, Mihyun
    Resto, Vicente A.
    Guo, Fangjian
    Berenson, Abbey B.
    [J]. VACCINE, 2017, 35 (27) : 3446 - 3451
  • [19] Cancer statistics, 2007
    Jemal, Ahmedin
    Siegel, Rebecca
    Ward, Elizabeth
    Murray, Taylor
    Xu, Jiaquan
    Thun, Michael J.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) : 43 - 66
  • [20] Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study
    Joura, Elmar A.
    Ulied, Angels
    Vandermeulen, Corinne
    Rua Figueroa, Milagrosa
    Seppa, Ilkka
    Hernandez Aguado, Juan Jose
    Ahonen, Anitta
    Reich, Olaf
    Virta, Miia
    Perino, Antonino
    Peris Tuser, Merce
    Peters, Klaus
    Origoni, Massimo
    Raspagliesi, Francesco
    Tjalma, Wiebren A. A.
    Tummers, Philippe
    Woelber, Linn
    Nieminen, Pekka
    van Damme, Pierre
    Sehouli, Jalid
    Fiol Ruiz, Gabriel
    Brucker, Sara
    Fehm, Tanja
    Cheon, Kyeongmi
    Rawat, Sonali
    Luxembourg, Alain
    Wittke, Frederick
    [J]. VACCINE, 2021, 39 (20) : 2800 - 2809